--Nestle SA has started a process to sell its peanut-allergy treatment Palforzia, Bloomberg reports, citing unnamed sources.

--Initial bids are expected next month, but no final decision has been made on the timing of any sale, Bloomberg reports.

--Nestle, which bought the maker of Palforzia in a $2.6 billion deal in 2020 and recently announced a $2.1 billion impairment charge on the medication, declined to comment.


Full story: https://bloom.bg/3y2fmuv


Write to Adria Calatayud at adria.calatayud@dowjones.com


(END) Dow Jones Newswires

03-02-23 0327ET